Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 180,921,792
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 19,327 M
  • EBITDA $ 22,656 M
  • 60-Month Beta 0.73
  • Price/Sales 3.91
  • Price/Cash Flow 8.73
  • Price/Book 6.22

Options Overview Details

View History
  • Implied Volatility 48.37% (+0.10%)
  • Historical Volatility 28.35%
  • IV Percentile 62%
  • IV Rank 44.86%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 5) 1.35 (3.34%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 73,453
  • Volume Avg (30-Day) 78,192
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 1,566,465
  • Open Int (30-Day) 1,537,997
  • Expected Range 39.17 to 41.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.87
  • Number of Estimates 5
  • High Estimate $0.94
  • Low Estimate $0.81
  • Prior Year $0.92
  • Growth Rate Est. (year over year) -5.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.12 +15.38%
on 03/30/26
41.41 -2.15%
on 04/16/26
+2.09 (+5.44%)
since 03/17/26
3-Month
35.12 +15.38%
on 03/30/26
64.16 -36.85%
on 01/23/26
-21.81 (-34.99%)
since 01/16/26
52-Week
35.12 +15.38%
on 03/30/26
81.44 -50.25%
on 06/13/25
-17.56 (-30.23%)
since 04/17/25

Most Recent Stories

More News
3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

NVO : 40.52 (-1.00%)
OZEM : 32.38 (+1.28%)
LLY : 927.03 (+2.55%)
GPCR : 50.75 (-5.14%)
THNR : 25.05 (+0.72%)
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?

Nuclear, pharma, and travel giants just made significant buyback announcements. However, not all of these are as confidence-inspiring as they may seem.

CEG : 296.21 (-0.98%)
NVO : 40.52 (-1.00%)
LLY : 927.03 (+2.55%)
CCL : 29.22 (+6.99%)
Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

NVO : 40.52 (-1.00%)
HIMS : 28.82 (+6.78%)
LLY : 927.03 (+2.55%)
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

PLAINSBORO, N.J. , March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy ® , Wegovy ® HD (semaglutide)...

NVO : 40.52 (-1.00%)
Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

NVO : 40.52 (-1.00%)
LLY : 927.03 (+2.55%)
MarketBeat Week in Review – 03/09 - 03/13

Stocks moved higher this week despite uncertainty over the Iran conflict and oil prices; economic indicators point to no change in interest rates next week

GOOGL : 341.68 (+1.68%)
NVDA : 201.68 (+1.68%)
AVGO : 406.54 (+2.03%)
TJX : 160.68 (+2.03%)
FCEL : 7.25 (-1.36%)
CVX : 183.99 (-2.21%)
HIMS : 28.82 (+6.78%)
NVO : 40.52 (-1.00%)
MTN : 133.22 (+3.02%)
HBAN : 16.85 (+1.69%)
UNF : 263.13 (+0.38%)
COST : 999.89 (+1.28%)
The Real Reason Eli Lilly Is Pouring $3 Billion Into China

Eli Lilly's major investment in China's manufacturing capacity is a strategic move to secure its supply chain and capture a vast, untapped growth market.

NVO : 40.52 (-1.00%)
LLY : 927.03 (+2.55%)
Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

HIMS : 28.82 (+6.78%)
NVO : 40.52 (-1.00%)
LLY : 927.03 (+2.55%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised...

NVO : 40.52 (-1.00%)
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

HIMS : 28.82 (+6.78%)
NVO : 40.52 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 41.92
2nd Resistance Point 41.60
1st Resistance Point 41.06
Last Price 40.52
1st Support Level 40.21
2nd Support Level 39.89
3rd Support Level 39.35

See More

52-Week High 81.44
Fibonacci 61.8% 63.75
Fibonacci 50% 58.28
Fibonacci 38.2% 52.81
Last Price 40.52
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.